

GLAXOSMITHKLINE PLC
Form 6-K
July 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 July 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial notification
 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--
-
- | | |
|------------------------------|--|
| b) Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
|------------------------------|--|
-
- | c) Price(s) and volume(s) | <table style="border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Price(s)</th> <th style="text-align: left;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.18</td> <td>1,497.674</td> </tr> <tr> <td>£16.18</td> <td>776.283</td> </tr> <tr> <td>£16.18</td> <td>2,556.747</td> </tr> </tbody> </table> | Price(s) | Volume(s) | £16.18 | 1,497.674 | £16.18 | 776.283 | £16.18 | 2,556.747 |
|---------------------------|---|----------|-----------|--------|-----------|--------|---------|--------|-----------|
| Price(s) | Volume(s) | | | | | | | | |
| £16.18 | 1,497.674 | | | | | | | | |
| £16.18 | 776.283 | | | | | | | | |
| £16.18 | 2,556.747 | | | | | | | | |
-
- | | |
|---------------------------|-----------|
| d) Aggregated information | 4,830.704 |
| Aggregated volume Price | £16.18 |
-
- e) Date of the transaction 2017-07-14
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

- | | | |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.18 | 1,165.640 |
| | £16.18 | 1,492.989 |

- | | |
|---------------------------|-----------|
| d) Aggregated information | 2,658.629 |
| Aggregated volume Price | £16.18 |

- e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Debruyne
 b) Position/status President, Global Vaccines
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.						
b) Nature of the transaction							
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.18</td> <td>298.166</td> </tr> <tr> <td>£16.18</td> <td>375.805</td> </tr> </table>	Price(s)	Volume(s)	£16.18	298.166	£16.18	375.805
Price(s)	Volume(s)						
£16.18	298.166						
£16.18	375.805						
d) Aggregated information	673.971						
Aggregated volume Price	£16.18						
e) Date of the transaction	2017-07-14						
f) Place of the transaction	n/a						

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr S Dingemans
 - b) Position/status Chief Financial Officer
 - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.						
b) Nature of the transaction							
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.18</td> <td>2,535.105</td> </tr> <tr> <td>£16.18</td> <td>2,745.620</td> </tr> </table>	Price(s)	Volume(s)	£16.18	2,535.105	£16.18	2,745.620
Price(s)	Volume(s)						
£16.18	2,535.105						
£16.18	2,745.620						
d) Aggregated information							

Aggregated volume Price	5,280.725 £16.18						
e) Date of the transaction	2017-07-14						
f) Place of the transaction	n/a						
1. Details of PDMR/person closely associated with them ('PCA')							
a) Name	Mr N Hirons						
b) Position/status	SVP, Global Ethics & Compliance						
c) Initial notification/ amendment	Initial notification						
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a) Name	GlaxoSmithKline plc						
b) LEI	5493000HZTVUYLO1D793						
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882						
a) Description of the financial instrument							
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.						
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£16.18</td> <td>565.161</td> </tr> <tr> <td>£16.18</td> <td>615.859</td> </tr> </table>	Price(s)	Volume(s)	£16.18	565.161	£16.18	615.859
Price(s)	Volume(s)						
£16.18	565.161						
£16.18	615.859						
d) Aggregated information	1,181.020 £16.18						
Aggregated volume Price							
e) Date of the transaction	2017-07-14						
f) Place of the transaction	n/a						
1. Details of PDMR/person closely associated with them ('PCA')							

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr S A Hussain
- b) Position/status President, Global Pharmaceuticals
- c) Initial notification/ amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
- 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - Ordinary shares of 25 pence each ('Ordinary Shares')
 - ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction
 - Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.18	2,649.200
£16.18	2,985.991
- d) Aggregated information
 - 5,635.191
 - £16.18
 - Aggregated volume Price
- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a

- 1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction
 Increase in notional interest
 in Ordinary Shares following
 the re-investment of
 dividends paid to
 shareholders on 13 July 2017
 on Ordinary Shares held in
 the Company's 2009
 Performance Share Plan.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.18 | 927.212 |
| £16.18 | 1,082.411 |

- d) Aggregated information 2,009.623
 Aggregated volume Price £16.18

- e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
 b) Position/status SVP, HR
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.18	1,236.288
£16.18	1,362.348

d) Aggregated information
Aggregated volume Price

2,598.636
£16.18

e) Date of the transaction 2017-07-14
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
b) Position/status President, Global Affairs
Initial
c) notification/ Initial notification
amendment

Details of the issuer, emission allowance
2. market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in

	the Company's 2009 Performance Share Plan.	
	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.18	715.284
	£16.18	783.821

d) Aggregated information	1,499.105
Aggregated volume Price	£16.18

e) Date of the transaction 2017-07-14

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
 b) Position/status President, R&D
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument
 Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.18	2,571.481
	£16.18	3,172.607

d) Aggregated information	
Aggregated volume Price	5,744.088
	£16.18

- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.18 | 158.334 |
| £16.18 | 149.637 |
- d) Aggregated information
- | | |
|-------------------|---------|
| Aggregated volume | 307.971 |
| Price | £16.18 |
- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: July 17, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc